{"id":"W2744441485","doi":"10.1016/j.lungcan.2017.07.038","title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; Docetaxel; Refractory (planetary science); Population; Placebo; Lung cancer; Clinical endpoint; Surgery; Randomized controlled trial; Oncology; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009708165,0.0004472926,0.00174175,0.0001499998,0.0001629555,0.00002845011,0.0001717923,0.00007210808,0.0006119526],"category_scores_gemma":[0.0000792424,0.0002271804,0.0001580903,0.0001086515,0.0001407695,0.0001893125,0.00003459934,0.00009999904,2.998568e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007995626,"about_ca_system_score_gemma":0.001588859,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01077411,"about_ca_topic_score_gemma":0.02349617,"domain_scores_codex":[0.9979326,0.00007287477,0.0006777883,0.0005805059,0.0003896697,0.0003466264],"domain_scores_gemma":[0.9966918,0.000327425,0.0015254,0.0008497459,0.0003713855,0.0002342262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4921384,0.008608459,0.4871347,0.0005513274,0.004259277,0.0001188979,0.005361603,0.0001590777,0.00002469073,9.118813e-7,0.0001364003,0.001506305],"study_design_scores_gemma":[0.8362101,0.005086447,0.1465651,0.00150547,0.008112038,2.742602e-7,0.0007168817,0.0008656578,0.0005042785,0.000001769354,0.0001234323,0.0003085443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815339,0.001801243,0.0001458113,0.000150627,0.0002148365,0.01246429,0.003577981,0.00001978319,0.00009152159],"genre_scores_gemma":[0.9821231,0.0003276533,0.0004195702,0.00007412017,0.00008260897,0.006211238,0.0002221838,0.00007717976,0.01046239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3440717,"threshold_uncertainty_score":0.9958133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02050992220569165,"score_gpt":0.3717403769572913,"score_spread":0.3512304547515997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}